Cytidine Deaminase Inhibitors (CDA) - Pipeline Insight, 2022
![](/report_cover/8047/cytidine-deaminase-inhibitors-cda-pipeline-insight_en.gif)
This report can be delivered to the clients within 24 Hours
DelveInsight’s, “Cytidine Deaminase Inhibitors (CDA) - Pipeline Insight, 2022” report provides comprehensive insights about 2+ companies and 3+ pipeline drugs in Cytidine Deaminase Inhibitors (CDA) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Cytidine Deaminase Inhibitors (CDA): Overview
Cytidine deaminase inhibitors are molecules that inhibit the activity of the enzyme cytidine deaminase. Cytidine deaminase is an evolutionarily conserved enzyme of the pyrimidine salvage pathway. It catalyzes the hydrolytic deamination of cytidine and deoxycytidine to form uridine and deoxyuridine, respectively. Human cytidine deaminase (CDA) is an enzyme prominent for its role in catalyzing metabolic processing of nucleoside-type anticancer and antiviral agents. It is thus a promising target for the development of small molecule therapeutic adjuvants. Cytidine deaminase inhibitors are considered as a potential and promising treatment for tumors with highly expressed CDA.
Report Highlights
This segment of the Cytidine Deaminase Inhibitors (CDA) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Cytidine Deaminase Inhibitors (CDA) Emerging Drugs
Further product details are provided in the report……..
Cytidine Deaminase Inhibitors (CDA): Therapeutic Assessment
This segment of the report provides insights about the different Cytidine Deaminase Inhibitors (CDA) drugs segregated based on following parameters that define the scope of the report, such as:
Cytidine Deaminase Inhibitors (CDA): Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Cytidine Deaminase Inhibitors (CDA) therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cytidine Deaminase Inhibitors (CDA) drugs.
Cytidine Deaminase Inhibitors (CDA) Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “Cytidine Deaminase Inhibitors (CDA) - Pipeline Insight, 2022” report provides comprehensive insights about 2+ companies and 3+ pipeline drugs in Cytidine Deaminase Inhibitors (CDA) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Cytidine Deaminase Inhibitors (CDA): Overview
Cytidine deaminase inhibitors are molecules that inhibit the activity of the enzyme cytidine deaminase. Cytidine deaminase is an evolutionarily conserved enzyme of the pyrimidine salvage pathway. It catalyzes the hydrolytic deamination of cytidine and deoxycytidine to form uridine and deoxyuridine, respectively. Human cytidine deaminase (CDA) is an enzyme prominent for its role in catalyzing metabolic processing of nucleoside-type anticancer and antiviral agents. It is thus a promising target for the development of small molecule therapeutic adjuvants. Cytidine deaminase inhibitors are considered as a potential and promising treatment for tumors with highly expressed CDA.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Cytidine Deaminase Inhibitors (CDA) R&D. The therapies under development are focused on novel approaches for Cytidine Deaminase Inhibitors (CDA).
This segment of the Cytidine Deaminase Inhibitors (CDA) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Cytidine Deaminase Inhibitors (CDA) Emerging Drugs
- ASTX727: Astex Pharmaceuticals
Further product details are provided in the report……..
Cytidine Deaminase Inhibitors (CDA): Therapeutic Assessment
This segment of the report provides insights about the different Cytidine Deaminase Inhibitors (CDA) drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Cytidine Deaminase Inhibitors (CDA)
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Cytidine Deaminase Inhibitors (CDA): Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Cytidine Deaminase Inhibitors (CDA) therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cytidine Deaminase Inhibitors (CDA) drugs.
Cytidine Deaminase Inhibitors (CDA) Report Insights
- Cytidine Deaminase Inhibitors (CDA) Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Cytidine Deaminase Inhibitors (CDA) drugs?
- How many Cytidine Deaminase Inhibitors (CDA) drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Cytidine Deaminase Inhibitors (CDA)?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Cytidine Deaminase Inhibitors (CDA) therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Cytidine Deaminase Inhibitors (CDA) and their status?
- What are the key designations that have been granted to the emerging drugs?
- Astex Pharmaceuticals
- Novo Nordisk
- ASTX727
- Decitabine/tetrahydrouridine
- ASTX-030
Introduction
Executive Summary
Cytidine Deaminase Inhibitors (CDA): Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Cytidine Deaminase Inhibitors (CDA) – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Cytidine Deaminase Inhibitors (CDA) companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Cytidine Deaminase Inhibitors (CDA) Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Registered)
Comparative Analysis
ASTX727: Astex Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
ASTX-030: Astex Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Cytidine Deaminase Inhibitors (CDA) Key Companies
Cytidine Deaminase Inhibitors (CDA) Key Products
Cytidine Deaminase Inhibitors (CDA)- Unmet Needs
Cytidine Deaminase Inhibitors (CDA)- Market Drivers and Barriers
Cytidine Deaminase Inhibitors (CDA)- Future Perspectives and Conclusion
Cytidine Deaminase Inhibitors (CDA) Analyst Views
Cytidine Deaminase Inhibitors (CDA) Key Companies
Appendix
Executive Summary
Cytidine Deaminase Inhibitors (CDA): Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Cytidine Deaminase Inhibitors (CDA) – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Cytidine Deaminase Inhibitors (CDA) companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Cytidine Deaminase Inhibitors (CDA) Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Registered)
Comparative Analysis
ASTX727: Astex Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
ASTX-030: Astex Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Cytidine Deaminase Inhibitors (CDA) Key Companies
Cytidine Deaminase Inhibitors (CDA) Key Products
Cytidine Deaminase Inhibitors (CDA)- Unmet Needs
Cytidine Deaminase Inhibitors (CDA)- Market Drivers and Barriers
Cytidine Deaminase Inhibitors (CDA)- Future Perspectives and Conclusion
Cytidine Deaminase Inhibitors (CDA) Analyst Views
Cytidine Deaminase Inhibitors (CDA) Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Cytidine Deaminase Inhibitors (CDA)
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Cytidine Deaminase Inhibitors (CDA)
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Cytidine Deaminase Inhibitors (CDA)
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Cytidine Deaminase Inhibitors (CDA)
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products